. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Pediatr Blood Cancer. 2018 Mar 30;65(7):e27033. doi: 10.1002/pbc.27033

TABLE 2.

Clinical trials data suggest that differences in early outcome relate to treatment, rather than to age

Location	Regimen	Children	AYA	Adult
North America	ABVE, ABVE-PC^30,32	5y – EFS: 87%	5y – EFS: 86%
North America	Stanford V or ABVD²⁹		5y – FFS (17–21y): 68%	5y – FFS (22–44y): 76%
Hungary⁹⁴	OEPA/OPPA ± COPP		5y-EFS: 83%
Hungary⁹⁴	ABVD		5y-EFS: 78%
Canada⁹⁵	ABVD
Canada⁹⁵	MOPP/ABVD⁹⁶		5y-PFS: 77%	5y-PFS: 80%
Germany ^97,98	ABVD		6y-FFTF: 80%	6y-FFTF: 80%
	COPP/ABVD		10-FFTF: 79%	10y-FFTF: 76%
	COPP/ABVD ± IMEP
	BEACOPP standard or escBEACOPP³⁴

EFS: Event-free survival; FFS or FFTF: failure-free survival or freedom from treatment failure; ABVE-PC: doxorubicin, bleomycin, vinblastine, etoposide, prednisone, and cyclophosphamide; DECA: dexamethasone, etoposide, cisplatin, and cytarabine; Stanford V: doxorubicin, vinblastine, nitrogen mustard, etoposide, vincristine, bleomycin, and prednisone. OEPA/OPPA: vincristine, etoposide, prednisone, doxorubicin/vincristine, prednisone, procarbazine, doxorubicin; COPP: Cyclophosphamide, vincristine, procarbazine, and prednisone; ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine; MOPP: Mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine; IMEP: Ifosfamide, methotrexate, etoposide; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine